IDx

Overview

US healthcare-AI company; cited by ari-leshno in 2026-05-19-saar-leshno-glaucoma-data-tracking as the FDA-clearance precedent for ophthalmology AI. The trick: rather than diagnosing, IDx’s approved system phrases its output as “this scan is normal” (a screening assertion), which clears a substantially lower regulatory bar than a diagnostic claim. Ari referenced this verbatim as the playbook for any future predictive-model layer on top of the proposed visual-field tracking product.

Relationships

• (no direct relationships in this KB yet.)

Notes

• Importance: defines the boundary between “SaaS we ship now” and “AI we ship after FDA.” Future-state ophthalmology-AI plays (deterioration prediction, treatment recommendation, missed-stroke detection) all live on the FDA side; the ari-leshno / yael visual-field tracking wedge is explicitly designed to live on the SaaS side first.

Mentioned in

• 2026-05-19-saar-leshno-glaucoma-data-tracking — cited as the FDA-clearance precedent / workaround for ophthalmology AI.